Sunho Biologics (HKSE:02898) Retained Earnings : HK$-435.70 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sunho Biologics's retained earnings for the quarter that ended in Dec. 2024 was HK$-435.70 Mil.

Sunho Biologics's quarterly retained earnings declined from Dec. 2023 (HK$-358.89 Mil) to Jun. 2024 (HK$-392.07 Mil) and declined from Jun. 2024 (HK$-392.07 Mil) to Dec. 2024 (HK$-435.70 Mil).

Sunho Biologics's annual retained earnings declined from Dec. 2022 (HK$-218.22 Mil) to Dec. 2023 (HK$-358.89 Mil) and declined from Dec. 2023 (HK$-358.89 Mil) to Dec. 2024 (HK$-435.70 Mil).

Sunho Biologics Retained Earnings Historical Data

The historical data trend for Sunho Biologics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics Retained Earnings Chart

Sunho Biologics Annual Data

Trend

Dec22

Dec23

Dec24

Retained Earnings

-218.22

-358.89

-435.70

Sunho Biologics Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24	Dec24
Retained Earnings	-218.22	-	-358.89	-392.07	-435.70

Sunho Biologics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Sunho Biologics (HKSE:02898) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Sunho Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN

Website

http://www.sunho-bio.com.cn

Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

Executives

Sunho Fortune Investments Limited	2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited	2301 Trustee
Zhang Feng	2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited	2101 Beneficial owner

Sunho Biologics Headlines

No Headlines